FHIRsmith: CodeSystem/CodeSystem-mii-cs-onko-weitere-klassifikationen-obds.json

FHIR IG analytics

Package	de.medizininformatikinitiative.kerndatensatz.onkologie
Resource Type	CodeSystem
Id	CodeSystem-mii-cs-onko-weitere-klassifikationen-obds.json
FHIR Version	R4
Source	https://medizininformatik-initiative.github.io/kerndatensatzmodul-onkologie/2027.0.0-ballot.1/CodeSystem-mii-cs-onko-weitere-klassifikationen-obds.html
URL	https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-weitere-klassifikationen-obds
Version	2027.0.0-ballot.1
Status	active
Date	2026-09-15T06:26:59+00:00
Name	MII_CS_Onko_Weitere_Klassifikationen_OBDS
Title	MII CodeSystem Onkologie - Weitere Klassifikationen oBDS
Realm	de
Description	oBDS-specific classification systems and scoring systems not yet covered by international terminologies (SNOMED CT, NCI Thesaurus). These codes supplement the existing ValueSet for additional classifications. Research required: Check if SNOMED CT or LOINC codes exist for these scoring systems before using oBDS-specific codes.
Content	complete

Resources that use this resource

ValueSet
de.medizininformatikinitiative.kerndatensatz.onkologie#2027.0.0-ballot.1	mii-vs-onko-weitere-klassifikationen-auspraegungen	MII Value Set Onkologie - Weitere Klassifikationen - Auspraegungen

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

English

Generated Narrative: CodeSystem mii-cs-onko-weitere-klassifikationen-obds

Profiles: CRMI Shareable CodeSystem, CRMI Publishable CodeSystem

This case-sensitive code system https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-weitere-klassifikationen-obds defines the following codes in an undefined hierarchy:

Lvl	Code	Display	Definition
1	binet	BINET Staging System	Staging system for chronic lymphocytic leukemia based on lymph node involvement and organ enlargement.
2	binet-a	BINET A	Early stage CLL: lymphocytosis in blood and bone marrow only
2	binet-b	BINET B	Intermediate stage CLL: lymphocytosis with enlarged lymph nodes or spleen/liver
2	binet-c	BINET C	Advanced stage CLL: lymphocytosis with anemia or thrombocytopenia
1	ann-arbor-stadium	Ann-Arbor Stadium	Staging system for Hodgkin and Non-Hodgkin lymphomas based on anatomical extent of disease.
2	ann-arbor-i	I	Single lymph node region or single extralymphatic organ
2	ann-arbor-ia	IA	Single lymph node region, asymptomatic
2	ann-arbor-iae	IAE	Single lymph node region with extranodal extension, asymptomatic
2	ann-arbor-ib	IB	Single lymph node region with B symptoms
2	ann-arbor-ibe	IBE	Single lymph node region with extranodal extension and B symptoms
2	ann-arbor-ie	IE	Single extralymphatic organ involvement
2	ann-arbor-ix	IX	Single lymph node region, symptoms unclear
2	ann-arbor-ixa	IXA	Single lymph node region, symptoms unclear, asymptomatic features
2	ann-arbor-ixae	IXAE	Single lymph node region with extranodal extension, symptoms unclear, asymptomatic features
2	ann-arbor-ixb	IXB	Single lymph node region, symptoms unclear, B symptom features
2	ann-arbor-ixbe	IXBE	Single lymph node region with extranodal extension, symptoms unclear, B symptom features
2	ann-arbor-ixe	IXE	Single extralymphatic organ, symptoms unclear
2	ann-arbor-ii	II	Two or more lymph node regions on same side of diaphragm
2	ann-arbor-ii1	II1	Two lymph node regions on same side of diaphragm
2	ann-arbor-ii1a	II1A	Two lymph node regions on same side of diaphragm, asymptomatic
2	ann-arbor-ii1ae	II1AE	Two lymph node regions on same side of diaphragm with extranodal extension, asymptomatic
2	ann-arbor-ii1b	II1B	Two lymph node regions on same side of diaphragm with B symptoms
2	ann-arbor-ii1be	II1BE	Two lymph node regions on same side of diaphragm with extranodal extension and B symptoms
2	ann-arbor-ii1e	II1E	Two lymph node regions on same side of diaphragm with extranodal extension
2	ann-arbor-ii1x	II1X	Two lymph node regions on same side of diaphragm, symptoms unclear
2	ann-arbor-ii1xa	II1XA	Two lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features
2	ann-arbor-ii1xae	II1XAE	Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features
2	ann-arbor-ii1xb	II1XB	Two lymph node regions on same side of diaphragm, symptoms unclear, B symptom features
2	ann-arbor-ii1xbe	II1XBE	Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features
2	ann-arbor-ii1xe	II1XE	Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear
2	ann-arbor-ii2	II2	Multiple lymph node regions on same side of diaphragm
2	ann-arbor-ii2a	II2A	Multiple lymph node regions on same side of diaphragm, asymptomatic
2	ann-arbor-ii2ae	II2AE	Multiple lymph node regions on same side of diaphragm with extranodal extension, asymptomatic
2	ann-arbor-ii2b	II2B	Multiple lymph node regions on same side of diaphragm with B symptoms
2	ann-arbor-ii2be	II2BE	Multiple lymph node regions on same side of diaphragm with extranodal extension and B symptoms
2	ann-arbor-ii2e	II2E	Multiple lymph node regions on same side of diaphragm with extranodal extension
2	ann-arbor-ii2x	II2X	Multiple lymph node regions on same side of diaphragm, symptoms unclear
2	ann-arbor-ii2xa	II2XA	Multiple lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features
2	ann-arbor-ii2xae	II2XAE	Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features
2	ann-arbor-ii2xb	II2XB	Multiple lymph node regions on same side of diaphragm, symptoms unclear, B symptom features
2	ann-arbor-ii2xbe	II2XBE	Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features
2	ann-arbor-ii2xe	II2XE	Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear
2	ann-arbor-iia	IIA	Two or more lymph node regions on same side of diaphragm, asymptomatic
2	ann-arbor-iiae	IIAE	Two or more lymph node regions on same side of diaphragm with extranodal extension, asymptomatic
2	ann-arbor-iib	IIB	Two or more lymph node regions on same side of diaphragm with B symptoms
2	ann-arbor-iibe	IIBE	Two or more lymph node regions on same side of diaphragm with extranodal extension and B symptoms
2	ann-arbor-iie	IIE	Two or more lymph node regions on same side of diaphragm with extranodal extension
2	ann-arbor-iix	IIX	Two or more lymph node regions on same side of diaphragm, symptoms unclear
2	ann-arbor-iixa	IIXA	Two or more lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features
2	ann-arbor-iixae	IIXAE	Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features
2	ann-arbor-iixb	IIXB	Two or more lymph node regions on same side of diaphragm, symptoms unclear, B symptom features
2	ann-arbor-iixbe	IIXBE	Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features
2	ann-arbor-iixe	IIXE	Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear
2	ann-arbor-iii	III	Lymph node regions on both sides of diaphragm
2	ann-arbor-iiia	IIIA	Lymph node regions on both sides of diaphragm, asymptomatic
2	ann-arbor-iiiae	IIIAE	Lymph node regions on both sides of diaphragm with extranodal extension, asymptomatic
2	ann-arbor-iiiaes	IIIAES	Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, asymptomatic
2	ann-arbor-iiias	IIIAS	Lymph node regions on both sides of diaphragm with spleen involvement, asymptomatic
2	ann-arbor-iiib	IIIB	Lymph node regions on both sides of diaphragm with B symptoms
2	ann-arbor-iiibe	IIIBE	Lymph node regions on both sides of diaphragm with extranodal extension and B symptoms
2	ann-arbor-iiibes	IIIBES	Lymph node regions on both sides of diaphragm with extranodal extension, spleen involvement, and B symptoms
2	ann-arbor-iiibs	IIIBS	Lymph node regions on both sides of diaphragm with spleen involvement and B symptoms
2	ann-arbor-iiie	IIIE	Lymph node regions on both sides of diaphragm with extranodal extension
2	ann-arbor-iiies	IIIES	Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement
2	ann-arbor-iiis	IIIS	Lymph node regions on both sides of diaphragm with spleen involvement
2	ann-arbor-iiix	IIIX	Lymph node regions on both sides of diaphragm, symptoms unclear
2	ann-arbor-iiixa	IIIXA	Lymph node regions on both sides of diaphragm, symptoms unclear, asymptomatic features
2	ann-arbor-iiixae	IIIXAE	Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear, asymptomatic features
2	ann-arbor-iiixaes	IIIXAES	Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear, asymptomatic features
2	ann-arbor-iiixas	IIIXAS	Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear, asymptomatic features
2	ann-arbor-iiixb	IIIXB	Lymph node regions on both sides of diaphragm, symptoms unclear, B symptom features
2	ann-arbor-iiixbe	IIIXBE	Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear, B symptom features
2	ann-arbor-iiixbes	IIIXBES	Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear, B symptom features
2	ann-arbor-iiixbs	IIIXBS	Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear, B symptom features
2	ann-arbor-iiixe	IIIXE	Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear
2	ann-arbor-iiixes	IIIXES	Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear
2	ann-arbor-iiixs	IIIXS	Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear
2	ann-arbor-iii1	III1	Limited lymph node regions on both sides of diaphragm
2	ann-arbor-iii1a	III1A	Limited lymph node regions on both sides of diaphragm, asymptomatic
2	ann-arbor-iii1b	III1B	Limited lymph node regions on both sides of diaphragm with B symptoms
2	ann-arbor-iii2	III2	Multiple lymph node regions on both sides of diaphragm
2	ann-arbor-iii2a	III2A	Multiple lymph node regions on both sides of diaphragm, asymptomatic
2	ann-arbor-iii2b	III2B	Multiple lymph node regions on both sides of diaphragm with B symptoms
2	ann-arbor-iv	IV	Disseminated involvement of one or more extralymphatic organs
2	ann-arbor-iva	IVA	Disseminated involvement of extralymphatic organs, asymptomatic
2	ann-arbor-ivae	IVAE	Disseminated involvement of extralymphatic organs with additional extranodal extension, asymptomatic
2	ann-arbor-ivb	IVB	Disseminated involvement of extralymphatic organs with B symptoms
2	ann-arbor-ivbe	IVBE	Disseminated involvement of extralymphatic organs with additional extranodal extension and B symptoms
2	ann-arbor-ive	IVE	Disseminated involvement of extralymphatic organs with extranodal extension
2	ann-arbor-ivx	IVX	Disseminated involvement of extralymphatic organs, symptoms unclear
2	ann-arbor-ivxa	IVXA	Disseminated involvement of extralymphatic organs, symptoms unclear, asymptomatic features
2	ann-arbor-ivxae	IVXAE	Disseminated involvement of extralymphatic organs with additional extranodal extension, symptoms unclear, asymptomatic features
2	ann-arbor-ivxb	IVXB	Disseminated involvement of extralymphatic organs, symptoms unclear, B symptom features
2	ann-arbor-ivxbe	IVXBE	Disseminated involvement of extralymphatic organs with additional extranodal extension, symptoms unclear, B symptom features
2	ann-arbor-ivxe	IVXE	Disseminated involvement of extralymphatic organs with extranodal extension, symptoms unclear
1	iss	International Staging System	Staging system for multiple myeloma based on serum beta-2 microglobulin and albumin levels.
2	iss-i	ISS I	Beta-2 microglobulin <3.5 mg/L and albumin ≥3.5 g/dL
2	iss-ii	ISS II	Not ISS I or ISS III
2	iss-iii	ISS III	Beta-2 microglobulin ≥5.5 mg/L
1	isswm	International Scoring System for Waldenström's Macroglobulinemia	Prognostic scoring system for Waldenström's macroglobulinemia based on age, beta-2 microglobulin, and albumin levels.
2	isswm-n	ISSWM Niedrig	Low risk: age ≤65 years, beta-2 microglobulin ≤3 mg/L, albumin >3.5 g/dL
2	isswm-i	ISSWM Intermediär	Intermediate risk: one adverse factor
2	isswm-h	ISSWM Hoch	High risk: age >65 years or beta-2 microglobulin >3 mg/L, or albumin ≤3.5 g/dL (≥2 factors)
1	who-grad	WHO Grade	World Health Organization grading system for central nervous system tumors based on histological features.
2	who-grad-i	WHO Grad I	Well-differentiated, slow-growing, low proliferative potential
2	who-grad-ii	WHO Grad II	Moderately differentiated, infiltrative, low proliferative potential
2	who-grad-iii	WHO Grad III	Poorly differentiated, anaplastic, high proliferative potential
2	who-grad-iv	WHO Grad IV	Poorly differentiated, high mitotic activity, necrosis, microvascular proliferation
1	formen	Formen	Classification of lymphoma forms distinguishing classical and variant presentations.
2	formen-k	Klassisch	Classical form of lymphoma presentation
2	formen-v	Variante	Variant form of lymphoma presentation
1	eln-klassifikation	ELN-Klassifikation	European LeukemiaNet risk stratification for acute myeloid leukemia based on cytogenetic and molecular genetic abnormalities.
2	eln-g	ELN Günstig	Favorable risk: good prognosis cytogenetic/molecular markers
2	eln-i1	ELN Intermediär I	Intermediate risk I: intermediate prognosis markers
2	eln-i2	ELN Intermediär II	Intermediate risk II: intermediate prognosis markers
2	eln-u	ELN Ungünstig	Unfavorable risk: poor prognosis cytogenetic/molecular markers
2	eln-cp	ELN Chronische Phase	Chronic phase (CML context)
2	eln-ap	ELN Akzelierte Phase	Accelerated phase (CML context)
2	eln-bk	ELN Blastenkrise	Blast crisis phase (CML context)
1	durie-salmon-stadium	Durie-Salmon Stadium	Multiple myeloma staging system based on tumor burden and organ function.
2	durie-salmon-i	Durie-Salmon I	Low tumor burden: hemoglobin >10 g/dL, calcium normal, no bone lesions
2	durie-salmon-ia	Durie-Salmon IA	Low tumor burden with normal renal function
2	durie-salmon-ib	Durie-Salmon IB	Low tumor burden with abnormal renal function
2	durie-salmon-ii	Durie-Salmon II	Intermediate tumor burden: neither stage I nor III criteria
2	durie-salmon-iia	Durie-Salmon IIA	Intermediate tumor burden with normal renal function
2	durie-salmon-iib	Durie-Salmon IIB	Intermediate tumor burden with abnormal renal function
2	durie-salmon-iii	Durie-Salmon III	High tumor burden: hemoglobin <8.5 g/dL, calcium elevated, extensive bone lesions
2	durie-salmon-iiia	Durie-Salmon IIIA	High tumor burden with normal renal function
2	durie-salmon-iiib	Durie-Salmon IIIB	High tumor burden with abnormal renal function
1	figo	FIGO	Staging system of the International Federation of Gynecology and Obstetrics (FIGO) for gynecological malignancies.
2	figo-i	FIGO I	Tumor confined to the organ of origin
2	figo-ia	FIGO IA	Stage I with limited local extent (entity-specific definition)
2	figo-ia1	FIGO IA1	Stage IA, subgroup 1 (e.g. cervix: measured stromal invasion <3 mm)
2	figo-ia2	FIGO IA2	Stage IA, subgroup 2 (e.g. cervix: measured stromal invasion 3 to <5 mm)
2	figo-ia3	FIGO IA3	Stage IA, subgroup 3 (entity-specific definition)
2	figo-ib	FIGO IB	Stage I with extended local extent (entity-specific definition)
2	figo-ib1	FIGO IB1	Stage IB, subgroup 1 (e.g. cervix: invasive carcinoma <2 cm)
2	figo-ib2	FIGO IB2	Stage IB, subgroup 2 (e.g. cervix: invasive carcinoma 2 to <4 cm)
2	figo-ib3	FIGO IB3	Stage IB, subgroup 3 (e.g. cervix: invasive carcinoma 4 cm or larger)
2	figo-ic	FIGO IC	Stage I with capsule rupture, surface involvement or malignant ascites
2	figo-ic1	FIGO IC1	Stage IC due to intraoperative surgical spill
2	figo-ic2	FIGO IC2	Stage IC due to preoperative capsule rupture or surface tumor
2	figo-ic3	FIGO IC3	Stage IC due to malignant cells in ascites or peritoneal washings
2	figo-ii	FIGO II	Tumor extending beyond the organ of origin within the pelvis
2	figo-iia	FIGO IIA	Stage II with limited extension (entity-specific definition)
2	figo-iia1	FIGO IIA1	Stage IIA, subgroup 1 (e.g. cervix: lesion <4 cm)
2	figo-iia2	FIGO IIA2	Stage IIA, subgroup 2 (e.g. cervix: lesion 4 cm or larger)
2	figo-iib	FIGO IIB	Stage II with extended extension (entity-specific definition)
2	figo-iic	FIGO IIC	Stage II with capsule rupture, surface involvement or malignant ascites (historical FIGO revisions)
2	figo-iii	FIGO III	Tumor with extrapelvic peritoneal spread and/or regional lymph node involvement
2	figo-iiia	FIGO IIIA	Stage III with microscopic or limited extrapelvic spread (entity-specific definition)
2	figo-iiia1	FIGO IIIA1	Stage III with retroperitoneal lymph node metastasis only
2	figo-iiia1i	FIGO IIIA1(i)	Stage IIIA1 with lymph node metastasis 10 mm or smaller
2	figo-iiia1ii	FIGO IIIA1(ii)	Stage IIIA1 with lymph node metastasis larger than 10 mm
2	figo-iiia2	FIGO IIIA2	Stage III with microscopic extrapelvic peritoneal involvement
2	figo-iiib	FIGO IIIB	Stage III with macroscopic extrapelvic peritoneal metastasis 2 cm or smaller
2	figo-iiic	FIGO IIIC	Stage III with macroscopic extrapelvic peritoneal metastasis larger than 2 cm and/or regional lymph node metastasis
2	figo-iiic1	FIGO IIIC1	Stage III with pelvic lymph node metastasis
2	figo-iiic1r	FIGO IIIC1r	Stage IIIC1 established by imaging
2	figo-iiic1p	FIGO IIIC1p	Stage IIIC1 established by pathology
2	figo-iiic2	FIGO IIIC2	Stage III with para-aortic lymph node metastasis
2	figo-iiic2r	FIGO IIIC2r	Stage IIIC2 established by imaging
2	figo-iiic2p	FIGO IIIC2p	Stage IIIC2 established by pathology
2	figo-iv	FIGO IV	Distant metastasis beyond the peritoneal cavity
2	figo-iva	FIGO IVA	Stage IV with spread to adjacent pelvic organs or pleural effusion with positive cytology (entity-specific definition)
2	figo-ivb	FIGO IVB	Stage IV with distant metastasis including extra-abdominal organs and lymph nodes
2	figo-ivc	FIGO IVC	Stage IV with distant metastasis (entity-specific definition)
1	bismuth	Bismuth	Classification system for hilar cholangiocarcinoma based on the extent of biliary involvement and resectability.
2	bismuth-i	Bismuth I	Tumor below confluence of left and right hepatic ducts
2	bismuth-ii	Bismuth II	Tumor reaching confluence but not involving secondary ducts
2	bismuth-iii	Bismuth III	Tumor involving confluence and either right or left secondary ducts
2	bismuth-iiia	Bismuth IIIA	Tumor involving confluence and right secondary ducts
2	bismuth-iiib	Bismuth IIIB	Tumor involving confluence and left secondary ducts
2	bismuth-iv	Bismuth IV	Tumor involving confluence and both right and left secondary ducts
1	masaoka	Masaoka	Staging system for thymomas based on invasiveness and extent of disease.
2	masaoka-i	Masaoka I	Encapsulated tumor without invasion
2	masaoka-ii	Masaoka II	Invasion into surrounding fatty tissue or mediastinal pleura
2	masaoka-iii	Masaoka III	Invasion into neighboring organs
2	masaoka-iv	Masaoka IV	Pleural or pericardial dissemination
2	masaoka-iva	Masaoka IVA	Pleural or pericardial implants
2	masaoka-ivb	Masaoka IVB	Lymphogenous or hematogenous metastasis
1	mitoserate-gist	Mitoserate-GIST	Mitotic rate assessment for gastrointestinal stromal tumors.
2	mitoserate-gist-n	Mitoserate-GIST Niedrig	Low mitotic rate: ≤5 mitoses per 50 HPF
2	mitoserate-gist-h	Mitoserate-GIST Hoch	High mitotic rate: >5 mitoses per 50 HPF
1	p16	p16	p16 protein expression status assessment.
2	p16-p	p16 Positiv	Positive p16 protein expression
2	p16-n	p16 Negativ	Negative p16 protein expression
1	eutos-score	EUTOS-Score	European Treatment and Outcome Study prognostic score for chronic myeloid leukemia.
2	eutos-score-n	EUTOS-Score Niedrigrisiko	Low risk EUTOS score: ≤87
2	eutos-score-h	EUTOS-Score Hochrisiko	High risk EUTOS score: >87
1	sanz-score	Sanz-Score	Risk assessment score for acute promyelocytic leukemia.
2	sanz-score-n	Sanz-Score Niedrig	Low risk: WBC <10x10⁹/L and platelets >40x10⁹/L
2	sanz-score-i	Sanz-Score Intermediär	Intermediate risk: WBC <10x10⁹/L and platelets ≤40x10⁹/L
2	sanz-score-h	Sanz-Score Hoch	High risk: WBC ≥10x10⁹/L
1	ipi	IPI	International Prognostic Index for aggressive non-Hodgkin lymphoma.
2	ipi-n	IPI Niedrig	Low risk: 0-1 risk factors
2	ipi-ni	IPI Niedrig-Intermediär	Low-intermediate risk: 2 risk factors
2	ipi-hi	IPI Hoch-Intermediär	High-intermediate risk: 3 risk factors
2	ipi-h	IPI Hoch	High risk: 4-5 risk factors
1	flipi	FLIPI	Follicular Lymphoma International Prognostic Index.
2	flipi-l	FLIPI Low risk	Low risk: 0-1 risk factors
2	flipi-i	FLIPI Intermediate risk	Intermediate risk: 2 risk factors
2	flipi-h	FLIPI High risk	High risk: ≥3 risk factors
1	mipi	MIPI	Mantle Cell Lymphoma International Prognostic Index.
2	mipi-n	MIPI Niedrig	Low risk MIPI score
2	mipi-i	MIPI Intermediär	Intermediate risk MIPI score
2	mipi-h	MIPI Hoch	High risk MIPI score
1	risikogruppen-ghsg	Risikogruppen GHSG	German Hodgkin Study Group risk stratification.
2	risikogruppen-ghsg-fr	GHSG Frühe	Early favorable risk group
2	risikogruppen-ghsg-i	GHSG Intermediär	Intermediate risk group
2	risikogruppen-ghsg-fo	GHSG Fortgeschritten	Advanced risk group
1	ipss	IPSS	International Prognostic Scoring System for myelodysplastic syndromes.
2	ipss-l	IPSS Low	Low risk: score 0
2	ipss-i1	IPSS Intermediate-I	Intermediate-1 risk: score 0.5-1.0
2	ipss-i2	IPSS Intermediate-II	Intermediate-2 risk: score 1.5-2.0
2	ipss-h	IPSS High risk	High risk: score ≥2.5
1	her2-neu	HER2-neu	HER2-neu protein expression and gene amplification status.
2	her2-neu-p	HER2-neu Positiv	Positive HER2-neu status (IHC 3+ or FISH amplified)
2	her2-neu-n	HER2-neu Negativ	Negative HER2-neu status (IHC 0-1+ or FISH not amplified)

German

Generated Narrative: CodeSystem mii-cs-onko-weitere-klassifikationen-obds

Profiles: CRMI Shareable CodeSystem, CRMI Publishable CodeSystem

Lvl	Code	Display	Definition
1	binet	BINET Staging System	Staging system for chronic lymphocytic leukemia based on lymph node involvement and organ enlargement.
2	binet-a	BINET A	Early stage CLL: lymphocytosis in blood and bone marrow only
2	binet-b	BINET B	Intermediate stage CLL: lymphocytosis with enlarged lymph nodes or spleen/liver
2	binet-c	BINET C	Advanced stage CLL: lymphocytosis with anemia or thrombocytopenia
1	ann-arbor-stadium	Ann-Arbor Stadium	Staging system for Hodgkin and Non-Hodgkin lymphomas based on anatomical extent of disease.
2	ann-arbor-i	I	Single lymph node region or single extralymphatic organ
2	ann-arbor-ia	IA	Single lymph node region, asymptomatic
2	ann-arbor-iae	IAE	Single lymph node region with extranodal extension, asymptomatic
2	ann-arbor-ib	IB	Single lymph node region with B symptoms
2	ann-arbor-ibe	IBE	Single lymph node region with extranodal extension and B symptoms
2	ann-arbor-ie	IE	Single extralymphatic organ involvement
2	ann-arbor-ix	IX	Single lymph node region, symptoms unclear
2	ann-arbor-ixa	IXA	Single lymph node region, symptoms unclear, asymptomatic features
2	ann-arbor-ixae	IXAE	Single lymph node region with extranodal extension, symptoms unclear, asymptomatic features
2	ann-arbor-ixb	IXB	Single lymph node region, symptoms unclear, B symptom features
2	ann-arbor-ixbe	IXBE	Single lymph node region with extranodal extension, symptoms unclear, B symptom features
2	ann-arbor-ixe	IXE	Single extralymphatic organ, symptoms unclear
2	ann-arbor-ii	II	Two or more lymph node regions on same side of diaphragm
2	ann-arbor-ii1	II1	Two lymph node regions on same side of diaphragm
2	ann-arbor-ii1a	II1A	Two lymph node regions on same side of diaphragm, asymptomatic
2	ann-arbor-ii1ae	II1AE	Two lymph node regions on same side of diaphragm with extranodal extension, asymptomatic
2	ann-arbor-ii1b	II1B	Two lymph node regions on same side of diaphragm with B symptoms
2	ann-arbor-ii1be	II1BE	Two lymph node regions on same side of diaphragm with extranodal extension and B symptoms
2	ann-arbor-ii1e	II1E	Two lymph node regions on same side of diaphragm with extranodal extension
2	ann-arbor-ii1x	II1X	Two lymph node regions on same side of diaphragm, symptoms unclear
2	ann-arbor-ii1xa	II1XA	Two lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features
2	ann-arbor-ii1xae	II1XAE	Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features
2	ann-arbor-ii1xb	II1XB	Two lymph node regions on same side of diaphragm, symptoms unclear, B symptom features
2	ann-arbor-ii1xbe	II1XBE	Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features
2	ann-arbor-ii1xe	II1XE	Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear
2	ann-arbor-ii2	II2	Multiple lymph node regions on same side of diaphragm
2	ann-arbor-ii2a	II2A	Multiple lymph node regions on same side of diaphragm, asymptomatic
2	ann-arbor-ii2ae	II2AE	Multiple lymph node regions on same side of diaphragm with extranodal extension, asymptomatic
2	ann-arbor-ii2b	II2B	Multiple lymph node regions on same side of diaphragm with B symptoms
2	ann-arbor-ii2be	II2BE	Multiple lymph node regions on same side of diaphragm with extranodal extension and B symptoms
2	ann-arbor-ii2e	II2E	Multiple lymph node regions on same side of diaphragm with extranodal extension
2	ann-arbor-ii2x	II2X	Multiple lymph node regions on same side of diaphragm, symptoms unclear
2	ann-arbor-ii2xa	II2XA	Multiple lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features
2	ann-arbor-ii2xae	II2XAE	Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features
2	ann-arbor-ii2xb	II2XB	Multiple lymph node regions on same side of diaphragm, symptoms unclear, B symptom features
2	ann-arbor-ii2xbe	II2XBE	Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features
2	ann-arbor-ii2xe	II2XE	Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear
2	ann-arbor-iia	IIA	Two or more lymph node regions on same side of diaphragm, asymptomatic
2	ann-arbor-iiae	IIAE	Two or more lymph node regions on same side of diaphragm with extranodal extension, asymptomatic
2	ann-arbor-iib	IIB	Two or more lymph node regions on same side of diaphragm with B symptoms
2	ann-arbor-iibe	IIBE	Two or more lymph node regions on same side of diaphragm with extranodal extension and B symptoms
2	ann-arbor-iie	IIE	Two or more lymph node regions on same side of diaphragm with extranodal extension
2	ann-arbor-iix	IIX	Two or more lymph node regions on same side of diaphragm, symptoms unclear
2	ann-arbor-iixa	IIXA	Two or more lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features
2	ann-arbor-iixae	IIXAE	Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features
2	ann-arbor-iixb	IIXB	Two or more lymph node regions on same side of diaphragm, symptoms unclear, B symptom features
2	ann-arbor-iixbe	IIXBE	Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features
2	ann-arbor-iixe	IIXE	Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear
2	ann-arbor-iii	III	Lymph node regions on both sides of diaphragm
2	ann-arbor-iiia	IIIA	Lymph node regions on both sides of diaphragm, asymptomatic
2	ann-arbor-iiiae	IIIAE	Lymph node regions on both sides of diaphragm with extranodal extension, asymptomatic
2	ann-arbor-iiiaes	IIIAES	Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, asymptomatic
2	ann-arbor-iiias	IIIAS	Lymph node regions on both sides of diaphragm with spleen involvement, asymptomatic
2	ann-arbor-iiib	IIIB	Lymph node regions on both sides of diaphragm with B symptoms
2	ann-arbor-iiibe	IIIBE	Lymph node regions on both sides of diaphragm with extranodal extension and B symptoms
2	ann-arbor-iiibes	IIIBES	Lymph node regions on both sides of diaphragm with extranodal extension, spleen involvement, and B symptoms
2	ann-arbor-iiibs	IIIBS	Lymph node regions on both sides of diaphragm with spleen involvement and B symptoms
2	ann-arbor-iiie	IIIE	Lymph node regions on both sides of diaphragm with extranodal extension
2	ann-arbor-iiies	IIIES	Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement
2	ann-arbor-iiis	IIIS	Lymph node regions on both sides of diaphragm with spleen involvement
2	ann-arbor-iiix	IIIX	Lymph node regions on both sides of diaphragm, symptoms unclear
2	ann-arbor-iiixa	IIIXA	Lymph node regions on both sides of diaphragm, symptoms unclear, asymptomatic features
2	ann-arbor-iiixae	IIIXAE	Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear, asymptomatic features
2	ann-arbor-iiixaes	IIIXAES	Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear, asymptomatic features
2	ann-arbor-iiixas	IIIXAS	Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear, asymptomatic features
2	ann-arbor-iiixb	IIIXB	Lymph node regions on both sides of diaphragm, symptoms unclear, B symptom features
2	ann-arbor-iiixbe	IIIXBE	Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear, B symptom features
2	ann-arbor-iiixbes	IIIXBES	Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear, B symptom features
2	ann-arbor-iiixbs	IIIXBS	Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear, B symptom features
2	ann-arbor-iiixe	IIIXE	Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear
2	ann-arbor-iiixes	IIIXES	Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear
2	ann-arbor-iiixs	IIIXS	Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear
2	ann-arbor-iii1	III1	Limited lymph node regions on both sides of diaphragm
2	ann-arbor-iii1a	III1A	Limited lymph node regions on both sides of diaphragm, asymptomatic
2	ann-arbor-iii1b	III1B	Limited lymph node regions on both sides of diaphragm with B symptoms
2	ann-arbor-iii2	III2	Multiple lymph node regions on both sides of diaphragm
2	ann-arbor-iii2a	III2A	Multiple lymph node regions on both sides of diaphragm, asymptomatic
2	ann-arbor-iii2b	III2B	Multiple lymph node regions on both sides of diaphragm with B symptoms
2	ann-arbor-iv	IV	Disseminated involvement of one or more extralymphatic organs
2	ann-arbor-iva	IVA	Disseminated involvement of extralymphatic organs, asymptomatic
2	ann-arbor-ivae	IVAE	Disseminated involvement of extralymphatic organs with additional extranodal extension, asymptomatic
2	ann-arbor-ivb	IVB	Disseminated involvement of extralymphatic organs with B symptoms
2	ann-arbor-ivbe	IVBE	Disseminated involvement of extralymphatic organs with additional extranodal extension and B symptoms
2	ann-arbor-ive	IVE	Disseminated involvement of extralymphatic organs with extranodal extension
2	ann-arbor-ivx	IVX	Disseminated involvement of extralymphatic organs, symptoms unclear
2	ann-arbor-ivxa	IVXA	Disseminated involvement of extralymphatic organs, symptoms unclear, asymptomatic features
2	ann-arbor-ivxae	IVXAE	Disseminated involvement of extralymphatic organs with additional extranodal extension, symptoms unclear, asymptomatic features
2	ann-arbor-ivxb	IVXB	Disseminated involvement of extralymphatic organs, symptoms unclear, B symptom features
2	ann-arbor-ivxbe	IVXBE	Disseminated involvement of extralymphatic organs with additional extranodal extension, symptoms unclear, B symptom features
2	ann-arbor-ivxe	IVXE	Disseminated involvement of extralymphatic organs with extranodal extension, symptoms unclear
1	iss	International Staging System	Staging system for multiple myeloma based on serum beta-2 microglobulin and albumin levels.
2	iss-i	ISS I	Beta-2 microglobulin <3.5 mg/L and albumin ≥3.5 g/dL
2	iss-ii	ISS II	Not ISS I or ISS III
2	iss-iii	ISS III	Beta-2 microglobulin ≥5.5 mg/L
1	isswm	International Scoring System for Waldenström's Macroglobulinemia	Prognostic scoring system for Waldenström's macroglobulinemia based on age, beta-2 microglobulin, and albumin levels.
2	isswm-n	ISSWM Niedrig	Low risk: age ≤65 years, beta-2 microglobulin ≤3 mg/L, albumin >3.5 g/dL
2	isswm-i	ISSWM Intermediär	Intermediate risk: one adverse factor
2	isswm-h	ISSWM Hoch	High risk: age >65 years or beta-2 microglobulin >3 mg/L, or albumin ≤3.5 g/dL (≥2 factors)
1	who-grad	WHO Grade	World Health Organization grading system for central nervous system tumors based on histological features.
2	who-grad-i	WHO Grad I	Well-differentiated, slow-growing, low proliferative potential
2	who-grad-ii	WHO Grad II	Moderately differentiated, infiltrative, low proliferative potential
2	who-grad-iii	WHO Grad III	Poorly differentiated, anaplastic, high proliferative potential
2	who-grad-iv	WHO Grad IV	Poorly differentiated, high mitotic activity, necrosis, microvascular proliferation
1	formen	Formen	Classification of lymphoma forms distinguishing classical and variant presentations.
2	formen-k	Klassisch	Classical form of lymphoma presentation
2	formen-v	Variante	Variant form of lymphoma presentation
1	eln-klassifikation	ELN-Klassifikation	European LeukemiaNet risk stratification for acute myeloid leukemia based on cytogenetic and molecular genetic abnormalities.
2	eln-g	ELN Günstig	Favorable risk: good prognosis cytogenetic/molecular markers
2	eln-i1	ELN Intermediär I	Intermediate risk I: intermediate prognosis markers
2	eln-i2	ELN Intermediär II	Intermediate risk II: intermediate prognosis markers
2	eln-u	ELN Ungünstig	Unfavorable risk: poor prognosis cytogenetic/molecular markers
2	eln-cp	ELN Chronische Phase	Chronic phase (CML context)
2	eln-ap	ELN Akzelierte Phase	Accelerated phase (CML context)
2	eln-bk	ELN Blastenkrise	Blast crisis phase (CML context)
1	durie-salmon-stadium	Durie-Salmon Stadium	Multiple myeloma staging system based on tumor burden and organ function.
2	durie-salmon-i	Durie-Salmon I	Low tumor burden: hemoglobin >10 g/dL, calcium normal, no bone lesions
2	durie-salmon-ia	Durie-Salmon IA	Low tumor burden with normal renal function
2	durie-salmon-ib	Durie-Salmon IB	Low tumor burden with abnormal renal function
2	durie-salmon-ii	Durie-Salmon II	Intermediate tumor burden: neither stage I nor III criteria
2	durie-salmon-iia	Durie-Salmon IIA	Intermediate tumor burden with normal renal function
2	durie-salmon-iib	Durie-Salmon IIB	Intermediate tumor burden with abnormal renal function
2	durie-salmon-iii	Durie-Salmon III	High tumor burden: hemoglobin <8.5 g/dL, calcium elevated, extensive bone lesions
2	durie-salmon-iiia	Durie-Salmon IIIA	High tumor burden with normal renal function
2	durie-salmon-iiib	Durie-Salmon IIIB	High tumor burden with abnormal renal function
1	figo	FIGO	Staging system of the International Federation of Gynecology and Obstetrics (FIGO) for gynecological malignancies.
2	figo-i	FIGO I	Tumor confined to the organ of origin
2	figo-ia	FIGO IA	Stage I with limited local extent (entity-specific definition)
2	figo-ia1	FIGO IA1	Stage IA, subgroup 1 (e.g. cervix: measured stromal invasion <3 mm)
2	figo-ia2	FIGO IA2	Stage IA, subgroup 2 (e.g. cervix: measured stromal invasion 3 to <5 mm)
2	figo-ia3	FIGO IA3	Stage IA, subgroup 3 (entity-specific definition)
2	figo-ib	FIGO IB	Stage I with extended local extent (entity-specific definition)
2	figo-ib1	FIGO IB1	Stage IB, subgroup 1 (e.g. cervix: invasive carcinoma <2 cm)
2	figo-ib2	FIGO IB2	Stage IB, subgroup 2 (e.g. cervix: invasive carcinoma 2 to <4 cm)
2	figo-ib3	FIGO IB3	Stage IB, subgroup 3 (e.g. cervix: invasive carcinoma 4 cm or larger)
2	figo-ic	FIGO IC	Stage I with capsule rupture, surface involvement or malignant ascites
2	figo-ic1	FIGO IC1	Stage IC due to intraoperative surgical spill
2	figo-ic2	FIGO IC2	Stage IC due to preoperative capsule rupture or surface tumor
2	figo-ic3	FIGO IC3	Stage IC due to malignant cells in ascites or peritoneal washings
2	figo-ii	FIGO II	Tumor extending beyond the organ of origin within the pelvis
2	figo-iia	FIGO IIA	Stage II with limited extension (entity-specific definition)
2	figo-iia1	FIGO IIA1	Stage IIA, subgroup 1 (e.g. cervix: lesion <4 cm)
2	figo-iia2	FIGO IIA2	Stage IIA, subgroup 2 (e.g. cervix: lesion 4 cm or larger)
2	figo-iib	FIGO IIB	Stage II with extended extension (entity-specific definition)
2	figo-iic	FIGO IIC	Stage II with capsule rupture, surface involvement or malignant ascites (historical FIGO revisions)
2	figo-iii	FIGO III	Tumor with extrapelvic peritoneal spread and/or regional lymph node involvement
2	figo-iiia	FIGO IIIA	Stage III with microscopic or limited extrapelvic spread (entity-specific definition)
2	figo-iiia1	FIGO IIIA1	Stage III with retroperitoneal lymph node metastasis only
2	figo-iiia1i	FIGO IIIA1(i)	Stage IIIA1 with lymph node metastasis 10 mm or smaller
2	figo-iiia1ii	FIGO IIIA1(ii)	Stage IIIA1 with lymph node metastasis larger than 10 mm
2	figo-iiia2	FIGO IIIA2	Stage III with microscopic extrapelvic peritoneal involvement
2	figo-iiib	FIGO IIIB	Stage III with macroscopic extrapelvic peritoneal metastasis 2 cm or smaller
2	figo-iiic	FIGO IIIC	Stage III with macroscopic extrapelvic peritoneal metastasis larger than 2 cm and/or regional lymph node metastasis
2	figo-iiic1	FIGO IIIC1	Stage III with pelvic lymph node metastasis
2	figo-iiic1r	FIGO IIIC1r	Stage IIIC1 established by imaging
2	figo-iiic1p	FIGO IIIC1p	Stage IIIC1 established by pathology
2	figo-iiic2	FIGO IIIC2	Stage III with para-aortic lymph node metastasis
2	figo-iiic2r	FIGO IIIC2r	Stage IIIC2 established by imaging
2	figo-iiic2p	FIGO IIIC2p	Stage IIIC2 established by pathology
2	figo-iv	FIGO IV	Distant metastasis beyond the peritoneal cavity
2	figo-iva	FIGO IVA	Stage IV with spread to adjacent pelvic organs or pleural effusion with positive cytology (entity-specific definition)
2	figo-ivb	FIGO IVB	Stage IV with distant metastasis including extra-abdominal organs and lymph nodes
2	figo-ivc	FIGO IVC	Stage IV with distant metastasis (entity-specific definition)
1	bismuth	Bismuth	Classification system for hilar cholangiocarcinoma based on the extent of biliary involvement and resectability.
2	bismuth-i	Bismuth I	Tumor below confluence of left and right hepatic ducts
2	bismuth-ii	Bismuth II	Tumor reaching confluence but not involving secondary ducts
2	bismuth-iii	Bismuth III	Tumor involving confluence and either right or left secondary ducts
2	bismuth-iiia	Bismuth IIIA	Tumor involving confluence and right secondary ducts
2	bismuth-iiib	Bismuth IIIB	Tumor involving confluence and left secondary ducts
2	bismuth-iv	Bismuth IV	Tumor involving confluence and both right and left secondary ducts
1	masaoka	Masaoka	Staging system for thymomas based on invasiveness and extent of disease.
2	masaoka-i	Masaoka I	Encapsulated tumor without invasion
2	masaoka-ii	Masaoka II	Invasion into surrounding fatty tissue or mediastinal pleura
2	masaoka-iii	Masaoka III	Invasion into neighboring organs
2	masaoka-iv	Masaoka IV	Pleural or pericardial dissemination
2	masaoka-iva	Masaoka IVA	Pleural or pericardial implants
2	masaoka-ivb	Masaoka IVB	Lymphogenous or hematogenous metastasis
1	mitoserate-gist	Mitoserate-GIST	Mitotic rate assessment for gastrointestinal stromal tumors.
2	mitoserate-gist-n	Mitoserate-GIST Niedrig	Low mitotic rate: ≤5 mitoses per 50 HPF
2	mitoserate-gist-h	Mitoserate-GIST Hoch	High mitotic rate: >5 mitoses per 50 HPF
1	p16	p16	p16 protein expression status assessment.
2	p16-p	p16 Positiv	Positive p16 protein expression
2	p16-n	p16 Negativ	Negative p16 protein expression
1	eutos-score	EUTOS-Score	European Treatment and Outcome Study prognostic score for chronic myeloid leukemia.
2	eutos-score-n	EUTOS-Score Niedrigrisiko	Low risk EUTOS score: ≤87
2	eutos-score-h	EUTOS-Score Hochrisiko	High risk EUTOS score: >87
1	sanz-score	Sanz-Score	Risk assessment score for acute promyelocytic leukemia.
2	sanz-score-n	Sanz-Score Niedrig	Low risk: WBC <10x10⁹/L and platelets >40x10⁹/L
2	sanz-score-i	Sanz-Score Intermediär	Intermediate risk: WBC <10x10⁹/L and platelets ≤40x10⁹/L
2	sanz-score-h	Sanz-Score Hoch	High risk: WBC ≥10x10⁹/L
1	ipi	IPI	International Prognostic Index for aggressive non-Hodgkin lymphoma.
2	ipi-n	IPI Niedrig	Low risk: 0-1 risk factors
2	ipi-ni	IPI Niedrig-Intermediär	Low-intermediate risk: 2 risk factors
2	ipi-hi	IPI Hoch-Intermediär	High-intermediate risk: 3 risk factors
2	ipi-h	IPI Hoch	High risk: 4-5 risk factors
1	flipi	FLIPI	Follicular Lymphoma International Prognostic Index.
2	flipi-l	FLIPI Low risk	Low risk: 0-1 risk factors
2	flipi-i	FLIPI Intermediate risk	Intermediate risk: 2 risk factors
2	flipi-h	FLIPI High risk	High risk: ≥3 risk factors
1	mipi	MIPI	Mantle Cell Lymphoma International Prognostic Index.
2	mipi-n	MIPI Niedrig	Low risk MIPI score
2	mipi-i	MIPI Intermediär	Intermediate risk MIPI score
2	mipi-h	MIPI Hoch	High risk MIPI score
1	risikogruppen-ghsg	Risikogruppen GHSG	German Hodgkin Study Group risk stratification.
2	risikogruppen-ghsg-fr	GHSG Frühe	Early favorable risk group
2	risikogruppen-ghsg-i	GHSG Intermediär	Intermediate risk group
2	risikogruppen-ghsg-fo	GHSG Fortgeschritten	Advanced risk group
1	ipss	IPSS	International Prognostic Scoring System for myelodysplastic syndromes.
2	ipss-l	IPSS Low	Low risk: score 0
2	ipss-i1	IPSS Intermediate-I	Intermediate-1 risk: score 0.5-1.0
2	ipss-i2	IPSS Intermediate-II	Intermediate-2 risk: score 1.5-2.0
2	ipss-h	IPSS High risk	High risk: score ≥2.5
1	her2-neu	HER2-neu	HER2-neu protein expression and gene amplification status.
2	her2-neu-p	HER2-neu Positiv	Positive HER2-neu status (IHC 3+ or FISH amplified)
2	her2-neu-n	HER2-neu Negativ	Negative HER2-neu status (IHC 0-1+ or FISH not amplified)

Source1

{
  "resourceType": "CodeSystem",
  "id": "mii-cs-onko-weitere-klassifikationen-obds",
  "meta": {
    "extension": [
      {
        "url": "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-license",
        "valueCode": "CC-BY-4.0"
      },
      {
        "extension": [
          {
            "url": "packageId",
            "valueId": "de.medizininformatikinitiative.kerndatensatz.onkologie"
          },
          {
            "url": "version",
            "valueString": "2027.0.0-ballot.1"
          },
          {
            "url": "uri",
            "valueUri": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko"
          }
        ],
        "url": "http://hl7.org/fhir/StructureDefinition/package-source"
      }
    ],
    "profile": [
      "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareablecodesystem",
      "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishablecodesystem"
    ]
  },
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
      "valueCode": "shareable"
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
      "valueCode": "publishable"
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-versionPolicy",
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/artifact-version-policy-codes",
            "code": "package",
            "display": "Package"
          }
        ]
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/resource-approvalDate",
      "valueDate": "2026-09-15"
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-topic",
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "code": "C3262"
          }
        ]
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-author",
      "valueContactDetail": {
        "telecom": [
          {
            "system": "email",
            "value": "thomas.debertshaeuser@charite.de"
          }
        ]
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-editor",
      "valueContactDetail": {
        "name": "Taskforce Core Data Set"
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
      "valueContactDetail": {
        "name": "Interoperability Working Group",
        "telecom": [
          {
            "system": "url",
            "value": "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"
          }
        ]
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
      "valueContactDetail": {
        "name": "National Steering Committee",
        "telecom": [
          {
            "system": "url",
            "value": "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"
          }
        ]
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
      "valueContactDetail": {
        "name": "Interoperability Working Group",
        "telecom": [
          {
            "system": "url",
            "value": "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"
          }
        ]
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
      "valueContactDetail": {
        "name": "National Steering Committee",
        "telecom": [
          {
            "system": "url",
            "value": "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"
          }
        ]
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-versionAlgorithm",
      "valueCoding": {
        "system": "http://hl7.org/fhir/version-algorithm",
        "code": "semver",
        "display": "SemVer"
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/resource-effectivePeriod",
      "valuePeriod": {
        "start": "2027"
      }
    }
  ],
  "url": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-weitere-klassifikationen-obds",
  "version": "2027.0.0-ballot.1",
  "name": "MII_CS_Onko_Weitere_Klassifikationen_OBDS",
  "title": "MII CodeSystem Onkologie - Weitere Klassifikationen oBDS",
  "status": "active",
  "experimental": false,
  "date": "2026-09-15T06:26:59+00:00",
  "publisher": "Medizininformatik Initiative",
  "contact": [
    {
      "name": "Medizininformatik Initiative",
      "telecom": [
        {
          "system": "url",
          "value": "https://www.medizininformatik-initiative.de/"
        }
      ]
    }
  ],
  "description": "oBDS-specific classification systems and scoring systems not yet covered by international terminologies (SNOMED CT, NCI Thesaurus). These codes supplement the existing ValueSet for additional classifications. Research required: Check if SNOMED CT or LOINC codes exist for these scoring systems before using oBDS-specific codes.",
  "jurisdiction": [
    {
      "coding": [
        {
          "system": "urn:iso:std:iso:3166",
          "code": "DE",
          "display": "Germany"
        }
      ]
    }
  ],
  "caseSensitive": true,
  "content": "complete",
  "count": 219,
  "concept": [
    {
      "code": "binet",
      "display": "BINET Staging System",
      "definition": "Staging system for chronic lymphocytic leukemia based on lymph node involvement and organ enlargement.",
      "concept": [
        {
          "code": "binet-a",
          "display": "BINET A",
          "definition": "Early stage CLL: lymphocytosis in blood and bone marrow only"
        },
        {
          "code": "binet-b",
          "display": "BINET B",
          "definition": "Intermediate stage CLL: lymphocytosis with enlarged lymph nodes or spleen/liver"
        },
        {
          "code": "binet-c",
          "display": "BINET C",
          "definition": "Advanced stage CLL: lymphocytosis with anemia or thrombocytopenia"
        }
      ]
    },
    {
      "code": "ann-arbor-stadium",
      "display": "Ann-Arbor Stadium",
      "definition": "Staging system for Hodgkin and Non-Hodgkin lymphomas based on anatomical extent of disease.",
      "concept": [
        {
          "code": "ann-arbor-i",
          "display": "I",
          "definition": "Single lymph node region or single extralymphatic organ"
        },
        {
          "code": "ann-arbor-ia",
          "display": "IA",
          "definition": "Single lymph node region, asymptomatic"
        },
        {
          "code": "ann-arbor-iae",
          "display": "IAE",
          "definition": "Single lymph node region with extranodal extension, asymptomatic"
        },
        {
          "code": "ann-arbor-ib",
          "display": "IB",
          "definition": "Single lymph node region with B symptoms"
        },
        {
          "code": "ann-arbor-ibe",
          "display": "IBE",
          "definition": "Single lymph node region with extranodal extension and B symptoms"
        },
        {
          "code": "ann-arbor-ie",
          "display": "IE",
          "definition": "Single extralymphatic organ involvement"
        },
        {
          "code": "ann-arbor-ix",
          "display": "IX",
          "definition": "Single lymph node region, symptoms unclear"
        },
        {
          "code": "ann-arbor-ixa",
          "display": "IXA",
          "definition": "Single lymph node region, symptoms unclear, asymptomatic features"
        },
        {
          "code": "ann-arbor-ixae",
          "display": "IXAE",
          "definition": "Single lymph node region with extranodal extension, symptoms unclear, asymptomatic features"
        },
        {
          "code": "ann-arbor-ixb",
          "display": "IXB",
          "definition": "Single lymph node region, symptoms unclear, B symptom features"
        },
        {
          "code": "ann-arbor-ixbe",
          "display": "IXBE",
          "definition": "Single lymph node region with extranodal extension, symptoms unclear, B symptom features"
        },
        {
          "code": "ann-arbor-ixe",
          "display": "IXE",
          "definition": "Single extralymphatic organ, symptoms unclear"
        },
        {
          "code": "ann-arbor-ii",
          "display": "II",
          "definition": "Two or more lymph node regions on same side of diaphragm"
        },
        {
          "code": "ann-arbor-ii1",
          "display": "II1",
          "definition": "Two lymph node regions on same side of diaphragm"
        },
        {
          "code": "ann-arbor-ii1a",
          "display": "II1A",
          "definition": "Two lymph node regions on same side of diaphragm, asymptomatic"
        },
        {
          "code": "ann-arbor-ii1ae",
          "display": "II1AE",
          "definition": "Two lymph node regions on same side of diaphragm with extranodal extension, asymptomatic"
        },
        {
          "code": "ann-arbor-ii1b",
          "display": "II1B",
          "definition": "Two lymph node regions on same side of diaphragm with B symptoms"
        },
        {
          "code": "ann-arbor-ii1be",
          "display": "II1BE",
          "definition": "Two lymph node regions on same side of diaphragm with extranodal extension and B symptoms"
        },
        {
          "code": "ann-arbor-ii1e",
          "display": "II1E",
          "definition": "Two lymph node regions on same side of diaphragm with extranodal extension"
        },
        {
          "code": "ann-arbor-ii1x",
          "display": "II1X",
          "definition": "Two lymph node regions on same side of diaphragm, symptoms unclear"
        },
        {
          "code": "ann-arbor-ii1xa",
          "display": "II1XA",
          "definition": "Two lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features"
        },
        {
          "code": "ann-arbor-ii1xae",
          "display": "II1XAE",
          "definition": "Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features"
        },
        {
          "code": "ann-arbor-ii1xb",
          "display": "II1XB",
          "definition": "Two lymph node regions on same side of diaphragm, symptoms unclear, B symptom features"
        },
        {
          "code": "ann-arbor-ii1xbe",
          "display": "II1XBE",
          "definition": "Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features"
        },
        {
          "code": "ann-arbor-ii1xe",
          "display": "II1XE",
          "definition": "Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear"
        },
        {
          "code": "ann-arbor-ii2",
          "display": "II2",
          "definition": "Multiple lymph node regions on same side of diaphragm"
        },
        {
          "code": "ann-arbor-ii2a",
          "display": "II2A",
          "definition": "Multiple lymph node regions on same side of diaphragm, asymptomatic"
        },
        {
          "code": "ann-arbor-ii2ae",
          "display": "II2AE",
          "definition": "Multiple lymph node regions on same side of diaphragm with extranodal extension, asymptomatic"
        },
        {
          "code": "ann-arbor-ii2b",
          "display": "II2B",
          "definition": "Multiple lymph node regions on same side of diaphragm with B symptoms"
        },
        {
          "code": "ann-arbor-ii2be",
          "display": "II2BE",
          "definition": "Multiple lymph node regions on same side of diaphragm with extranodal extension and B symptoms"
        },
        {
          "code": "ann-arbor-ii2e",
          "display": "II2E",
          "definition": "Multiple lymph node regions on same side of diaphragm with extranodal extension"
        },
        {
          "code": "ann-arbor-ii2x",
          "display": "II2X",
          "definition": "Multiple lymph node regions on same side of diaphragm, symptoms unclear"
        },
        {
          "code": "ann-arbor-ii2xa",
          "display": "II2XA",
          "definition": "Multiple lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features"
        },
        {
          "code": "ann-arbor-ii2xae",
          "display": "II2XAE",
          "definition": "Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features"
        },
        {
          "code": "ann-arbor-ii2xb",
          "display": "II2XB",
          "definition": "Multiple lymph node regions on same side of diaphragm, symptoms unclear, B symptom features"
        },
        {
          "code": "ann-arbor-ii2xbe",
          "display": "II2XBE",
          "definition": "Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features"
        },
        {
          "code": "ann-arbor-ii2xe",
          "display": "II2XE",
          "definition": "Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear"
        },
        {
          "code": "ann-arbor-iia",
          "display": "IIA",
          "definition": "Two or more lymph node regions on same side of diaphragm, asymptomatic"
        },
        {
          "code": "ann-arbor-iiae",
          "display": "IIAE",
          "definition": "Two or more lymph node regions on same side of diaphragm with extranodal extension, asymptomatic"
        },
        {
          "code": "ann-arbor-iib",
          "display": "IIB",
          "definition": "Two or more lymph node regions on same side of diaphragm with B symptoms"
        },
        {
          "code": "ann-arbor-iibe",
          "display": "IIBE",
          "definition": "Two or more lymph node regions on same side of diaphragm with extranodal extension and B symptoms"
        },
        {
          "code": "ann-arbor-iie",
          "display": "IIE",
          "definition": "Two or more lymph node regions on same side of diaphragm with extranodal extension"
        },
        {
          "code": "ann-arbor-iix",
          "display": "IIX",
          "definition": "Two or more lymph node regions on same side of diaphragm, symptoms unclear"
        },
        {
          "code": "ann-arbor-iixa",
          "display": "IIXA",
          "definition": "Two or more lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features"
        },
        {
          "code": "ann-arbor-iixae",
          "display": "IIXAE",
          "definition": "Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features"
        },
        {
          "code": "ann-arbor-iixb",
          "display": "IIXB",
          "definition": "Two or more lymph node regions on same side of diaphragm, symptoms unclear, B symptom features"
        },
        {
          "code": "ann-arbor-iixbe",
          "display": "IIXBE",
          "definition": "Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features"
        },
        {
          "code": "ann-arbor-iixe",
          "display": "IIXE",
          "definition": "Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear"
        },
        {
          "code": "ann-arbor-iii",
          "display": "III",
          "definition": "Lymph node regions on both sides of diaphragm"
        },
        {
          "code": "ann-arbor-iiia",
          "display": "IIIA",
          "definition": "Lymph node regions on both sides of diaphragm, asymptomatic"
        },
        {
          "code": "ann-arbor-iiiae",
          "display": "IIIAE",
          "definition": "Lymph node regions on both sides of diaphragm with extranodal extension, asymptomatic"
        },
        {
          "code": "ann-arbor-iiiaes",
          "display": "IIIAES",
          "definition": "Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, asymptomatic"
        },
        {
          "code": "ann-arbor-iiias",
          "display": "IIIAS",
          "definition": "Lymph node regions on both sides of diaphragm with spleen involvement, asymptomatic"
        },
        {
          "code": "ann-arbor-iiib",
          "display": "IIIB",
          "definition": "Lymph node regions on both sides of diaphragm with B symptoms"
        },
        {
          "code": "ann-arbor-iiibe",
          "display": "IIIBE",
          "definition": "Lymph node regions on both sides of diaphragm with extranodal extension and B symptoms"
        },
        {
          "code": "ann-arbor-iiibes",
          "display": "IIIBES",
          "definition": "Lymph node regions on both sides of diaphragm with extranodal extension, spleen involvement, and B symptoms"
        },
        {
          "code": "ann-arbor-iiibs",
          "display": "IIIBS",
          "definition": "Lymph node regions on both sides of diaphragm with spleen involvement and B symptoms"
        },
        {
          "code": "ann-arbor-iiie",
          "display": "IIIE",
          "definition": "Lymph node regions on both sides of diaphragm with extranodal extension"
        },
        {
          "code": "ann-arbor-iiies",
          "display": "IIIES",
          "definition": "Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement"
        },
        {
          "code": "ann-arbor-iiis",
          "display": "IIIS",
          "definition": "Lymph node regions on both sides of diaphragm with spleen involvement"
        },
        {
          "code": "ann-arbor-iiix",
          "display": "IIIX",
          "definition": "Lymph node regions on both sides of diaphragm, symptoms unclear"
        },
        {
          "code": "ann-arbor-iiixa",
          "display": "IIIXA",
          "definition": "Lymph node regions on both sides of diaphragm, symptoms unclear, asymptomatic features"
        },
        {
          "code": "ann-arbor-iiixae",
          "display": "IIIXAE",
          "definition": "Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear, asymptomatic features"
        },
        {
          "code": "ann-arbor-iiixaes",
          "display": "IIIXAES",
          "definition": "Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear, asymptomatic features"
        },
        {
          "code": "ann-arbor-iiixas",
          "display": "IIIXAS",
          "definition": "Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear, asymptomatic features"
        },
        {
          "code": "ann-arbor-iiixb",
          "display": "IIIXB",
          "definition": "Lymph node regions on both sides of diaphragm, symptoms unclear, B symptom features"
        },
        {
          "code": "ann-arbor-iiixbe",
          "display": "IIIXBE",
          "definition": "Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear, B symptom features"
        },
        {
          "code": "ann-arbor-iiixbes",
          "display": "IIIXBES",
          "definition": "Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear, B symptom features"
        },
        {
          "code": "ann-arbor-iiixbs",
          "display": "IIIXBS",
          "definition": "Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear, B symptom features"
        },
        {
          "code": "ann-arbor-iiixe",
          "display": "IIIXE",
          "definition": "Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear"
        },
        {
          "code": "ann-arbor-iiixes",
          "display": "IIIXES",
          "definition": "Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear"
        },
        {
          "code": "ann-arbor-iiixs",
          "display": "IIIXS",
          "definition": "Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear"
        },
        {
          "code": "ann-arbor-iii1",
          "display": "III1",
          "definition": "Limited lymph node regions on both sides of diaphragm"
        },
        {
          "code": "ann-arbor-iii1a",
          "display": "III1A",
          "definition": "Limited lymph node regions on both sides of diaphragm, asymptomatic"
        },
        {
          "code": "ann-arbor-iii1b",
          "display": "III1B",
          "definition": "Limited lymph node regions on both sides of diaphragm with B symptoms"
        },
        {
          "code": "ann-arbor-iii2",
          "display": "III2",
          "definition": "Multiple lymph node regions on both sides of diaphragm"
        },
        {
          "code": "ann-arbor-iii2a",
          "display": "III2A",
          "definition": "Multiple lymph node regions on both sides of diaphragm, asymptomatic"
        },
        {
          "code": "ann-arbor-iii2b",
          "display": "III2B",
          "definition": "Multiple lymph node regions on both sides of diaphragm with B symptoms"
        },
        {
          "code": "ann-arbor-iv",
          "display": "IV",
          "definition": "Disseminated involvement of one or more extralymphatic organs"
        },
        {
          "code": "ann-arbor-iva",
          "display": "IVA",
          "definition": "Disseminated involvement of extralymphatic organs, asymptomatic"
        },
        {
          "code": "ann-arbor-ivae",
          "display": "IVAE",
          "definition": "Disseminated involvement of extralymphatic organs with additional extranodal extension, asymptomatic"
        },
        {
          "code": "ann-arbor-ivb",
          "display": "IVB",
          "definition": "Disseminated involvement of extralymphatic organs with B symptoms"
        },
        {
          "code": "ann-arbor-ivbe",
          "display": "IVBE",
          "definition": "Disseminated involvement of extralymphatic organs with additional extranodal extension and B symptoms"
        },
        {
          "code": "ann-arbor-ive",
          "display": "IVE",
          "definition": "Disseminated involvement of extralymphatic organs with extranodal extension"
        },
        {
          "code": "ann-arbor-ivx",
          "display": "IVX",
          "definition": "Disseminated involvement of extralymphatic organs, symptoms unclear"
        },
        {
          "code": "ann-arbor-ivxa",
          "display": "IVXA",
          "definition": "Disseminated involvement of extralymphatic organs, symptoms unclear, asymptomatic features"
        },
        {
          "code": "ann-arbor-ivxae",
          "display": "IVXAE",
          "definition": "Disseminated involvement of extralymphatic organs with additional extranodal extension, symptoms unclear, asymptomatic features"
        },
        {
          "code": "ann-arbor-ivxb",
          "display": "IVXB",
          "definition": "Disseminated involvement of extralymphatic organs, symptoms unclear, B symptom features"
        },
        {
          "code": "ann-arbor-ivxbe",
          "display": "IVXBE",
          "definition": "Disseminated involvement of extralymphatic organs with additional extranodal extension, symptoms unclear, B symptom features"
        },
        {
          "code": "ann-arbor-ivxe",
          "display": "IVXE",
          "definition": "Disseminated involvement of extralymphatic organs with extranodal extension, symptoms unclear"
        }
      ]
    },
    {
      "code": "iss",
      "display": "International Staging System",
      "definition": "Staging system for multiple myeloma based on serum beta-2 microglobulin and albumin levels.",
      "concept": [
        {
          "code": "iss-i",
          "display": "ISS I",
          "definition": "Beta-2 microglobulin <3.5 mg/L and albumin ≥3.5 g/dL"
        },
        {
          "code": "iss-ii",
          "display": "ISS II",
          "definition": "Not ISS I or ISS III"
        },
        {
          "code": "iss-iii",
          "display": "ISS III",
          "definition": "Beta-2 microglobulin ≥5.5 mg/L"
        }
      ]
    },
    {
      "code": "isswm",
      "display": "International Scoring System for Waldenström's Macroglobulinemia",
      "definition": "Prognostic scoring system for Waldenström's macroglobulinemia based on age, beta-2 microglobulin, and albumin levels.",
      "concept": [
        {
          "code": "isswm-n",
          "display": "ISSWM Niedrig",
          "definition": "Low risk: age ≤65 years, beta-2 microglobulin ≤3 mg/L, albumin >3.5 g/dL"
        },
        {
          "code": "isswm-i",
          "display": "ISSWM Intermediär",
          "definition": "Intermediate risk: one adverse factor"
        },
        {
          "code": "isswm-h",
          "display": "ISSWM Hoch",
          "definition": "High risk: age >65 years or beta-2 microglobulin >3 mg/L, or albumin ≤3.5 g/dL (≥2 factors)"
        }
      ]
    },
    {
      "code": "who-grad",
      "display": "WHO Grade",
      "definition": "World Health Organization grading system for central nervous system tumors based on histological features.",
      "concept": [
        {
          "code": "who-grad-i",
          "display": "WHO Grad I",
          "definition": "Well-differentiated, slow-growing, low proliferative potential"
        },
        {
          "code": "who-grad-ii",
          "display": "WHO Grad II",
          "definition": "Moderately differentiated, infiltrative, low proliferative potential"
        },
        {
          "code": "who-grad-iii",
          "display": "WHO Grad III",
          "definition": "Poorly differentiated, anaplastic, high proliferative potential"
        },
        {
          "code": "who-grad-iv",
          "display": "WHO Grad IV",
          "definition": "Poorly differentiated, high mitotic activity, necrosis, microvascular proliferation"
        }
      ]
    },
    {
      "code": "formen",
      "display": "Formen",
      "definition": "Classification of lymphoma forms distinguishing classical and variant presentations.",
      "concept": [
        {
          "code": "formen-k",
          "display": "Klassisch",
          "definition": "Classical form of lymphoma presentation"
        },
        {
          "code": "formen-v",
          "display": "Variante",
          "definition": "Variant form of lymphoma presentation"
        }
      ]
    },
    {
      "code": "eln-klassifikation",
      "display": "ELN-Klassifikation",
      "definition": "European LeukemiaNet risk stratification for acute myeloid leukemia based on cytogenetic and molecular genetic abnormalities.",
      "concept": [
        {
          "code": "eln-g",
          "display": "ELN Günstig",
          "definition": "Favorable risk: good prognosis cytogenetic/molecular markers"
        },
        {
          "code": "eln-i1",
          "display": "ELN Intermediär I",
          "definition": "Intermediate risk I: intermediate prognosis markers"
        },
        {
          "code": "eln-i2",
          "display": "ELN Intermediär II",
          "definition": "Intermediate risk II: intermediate prognosis markers"
        },
        {
          "code": "eln-u",
          "display": "ELN Ungünstig",
          "definition": "Unfavorable risk: poor prognosis cytogenetic/molecular markers"
        },
        {
          "code": "eln-cp",
          "display": "ELN Chronische Phase",
          "definition": "Chronic phase (CML context)"
        },
        {
          "code": "eln-ap",
          "display": "ELN Akzelierte Phase",
          "definition": "Accelerated phase (CML context)"
        },
        {
          "code": "eln-bk",
          "display": "ELN Blastenkrise",
          "definition": "Blast crisis phase (CML context)"
        }
      ]
    },
    {
      "code": "durie-salmon-stadium",
      "display": "Durie-Salmon Stadium",
      "definition": "Multiple myeloma staging system based on tumor burden and organ function.",
      "concept": [
        {
          "code": "durie-salmon-i",
          "display": "Durie-Salmon I",
          "definition": "Low tumor burden: hemoglobin >10 g/dL, calcium normal, no bone lesions"
        },
        {
          "code": "durie-salmon-ia",
          "display": "Durie-Salmon IA",
          "definition": "Low tumor burden with normal renal function"
        },
        {
          "code": "durie-salmon-ib",
          "display": "Durie-Salmon IB",
          "definition": "Low tumor burden with abnormal renal function"
        },
        {
          "code": "durie-salmon-ii",
          "display": "Durie-Salmon II",
          "definition": "Intermediate tumor burden: neither stage I nor III criteria"
        },
        {
          "code": "durie-salmon-iia",
          "display": "Durie-Salmon IIA",
          "definition": "Intermediate tumor burden with normal renal function"
        },
        {
          "code": "durie-salmon-iib",
          "display": "Durie-Salmon IIB",
          "definition": "Intermediate tumor burden with abnormal renal function"
        },
        {
          "code": "durie-salmon-iii",
          "display": "Durie-Salmon III",
          "definition": "High tumor burden: hemoglobin <8.5 g/dL, calcium elevated, extensive bone lesions"
        },
        {
          "code": "durie-salmon-iiia",
          "display": "Durie-Salmon IIIA",
          "definition": "High tumor burden with normal renal function"
        },
        {
          "code": "durie-salmon-iiib",
          "display": "Durie-Salmon IIIB",
          "definition": "High tumor burden with abnormal renal function"
        }
      ]
    },
    {
      "code": "figo",
      "display": "FIGO",
      "definition": "Staging system of the International Federation of Gynecology and Obstetrics (FIGO) for gynecological malignancies.",
      "concept": [
        {
          "code": "figo-i",
          "display": "FIGO I",
          "definition": "Tumor confined to the organ of origin"
        },
        {
          "code": "figo-ia",
          "display": "FIGO IA",
          "definition": "Stage I with limited local extent (entity-specific definition)"
        },
        {
          "code": "figo-ia1",
          "display": "FIGO IA1",
          "definition": "Stage IA, subgroup 1 (e.g. cervix: measured stromal invasion <3 mm)"
        },
        {
          "code": "figo-ia2",
          "display": "FIGO IA2",
          "definition": "Stage IA, subgroup 2 (e.g. cervix: measured stromal invasion 3 to <5 mm)"
        },
        {
          "code": "figo-ia3",
          "display": "FIGO IA3",
          "definition": "Stage IA, subgroup 3 (entity-specific definition)"
        },
        {
          "code": "figo-ib",
          "display": "FIGO IB",
          "definition": "Stage I with extended local extent (entity-specific definition)"
        },
        {
          "code": "figo-ib1",
          "display": "FIGO IB1",
          "definition": "Stage IB, subgroup 1 (e.g. cervix: invasive carcinoma <2 cm)"
        },
        {
          "code": "figo-ib2",
          "display": "FIGO IB2",
          "definition": "Stage IB, subgroup 2 (e.g. cervix: invasive carcinoma 2 to <4 cm)"
        },
        {
          "code": "figo-ib3",
          "display": "FIGO IB3",
          "definition": "Stage IB, subgroup 3 (e.g. cervix: invasive carcinoma 4 cm or larger)"
        },
        {
          "code": "figo-ic",
          "display": "FIGO IC",
          "definition": "Stage I with capsule rupture, surface involvement or malignant ascites"
        },
        {
          "code": "figo-ic1",
          "display": "FIGO IC1",
          "definition": "Stage IC due to intraoperative surgical spill"
        },
        {
          "code": "figo-ic2",
          "display": "FIGO IC2",
          "definition": "Stage IC due to preoperative capsule rupture or surface tumor"
        },
        {
          "code": "figo-ic3",
          "display": "FIGO IC3",
          "definition": "Stage IC due to malignant cells in ascites or peritoneal washings"
        },
        {
          "code": "figo-ii",
          "display": "FIGO II",
          "definition": "Tumor extending beyond the organ of origin within the pelvis"
        },
        {
          "code": "figo-iia",
          "display": "FIGO IIA",
          "definition": "Stage II with limited extension (entity-specific definition)"
        },
        {
          "code": "figo-iia1",
          "display": "FIGO IIA1",
          "definition": "Stage IIA, subgroup 1 (e.g. cervix: lesion <4 cm)"
        },
        {
          "code": "figo-iia2",
          "display": "FIGO IIA2",
          "definition": "Stage IIA, subgroup 2 (e.g. cervix: lesion 4 cm or larger)"
        },
        {
          "code": "figo-iib",
          "display": "FIGO IIB",
          "definition": "Stage II with extended extension (entity-specific definition)"
        },
        {
          "code": "figo-iic",
          "display": "FIGO IIC",
          "definition": "Stage II with capsule rupture, surface involvement or malignant ascites (historical FIGO revisions)"
        },
        {
          "code": "figo-iii",
          "display": "FIGO III",
          "definition": "Tumor with extrapelvic peritoneal spread and/or regional lymph node involvement"
        },
        {
          "code": "figo-iiia",
          "display": "FIGO IIIA",
          "definition": "Stage III with microscopic or limited extrapelvic spread (entity-specific definition)"
        },
        {
          "code": "figo-iiia1",
          "display": "FIGO IIIA1",
          "definition": "Stage III with retroperitoneal lymph node metastasis only"
        },
        {
          "code": "figo-iiia1i",
          "display": "FIGO IIIA1(i)",
          "definition": "Stage IIIA1 with lymph node metastasis 10 mm or smaller"
        },
        {
          "code": "figo-iiia1ii",
          "display": "FIGO IIIA1(ii)",
          "definition": "Stage IIIA1 with lymph node metastasis larger than 10 mm"
        },
        {
          "code": "figo-iiia2",
          "display": "FIGO IIIA2",
          "definition": "Stage III with microscopic extrapelvic peritoneal involvement"
        },
        {
          "code": "figo-iiib",
          "display": "FIGO IIIB",
          "definition": "Stage III with macroscopic extrapelvic peritoneal metastasis 2 cm or smaller"
        },
        {
          "code": "figo-iiic",
          "display": "FIGO IIIC",
          "definition": "Stage III with macroscopic extrapelvic peritoneal metastasis larger than 2 cm and/or regional lymph node metastasis"
        },
        {
          "code": "figo-iiic1",
          "display": "FIGO IIIC1",
          "definition": "Stage III with pelvic lymph node metastasis"
        },
        {
          "code": "figo-iiic1r",
          "display": "FIGO IIIC1r",
          "definition": "Stage IIIC1 established by imaging"
        },
        {
          "code": "figo-iiic1p",
          "display": "FIGO IIIC1p",
          "definition": "Stage IIIC1 established by pathology"
        },
        {
          "code": "figo-iiic2",
          "display": "FIGO IIIC2",
          "definition": "Stage III with para-aortic lymph node metastasis"
        },
        {
          "code": "figo-iiic2r",
          "display": "FIGO IIIC2r",
          "definition": "Stage IIIC2 established by imaging"
        },
        {
          "code": "figo-iiic2p",
          "display": "FIGO IIIC2p",
          "definition": "Stage IIIC2 established by pathology"
        },
        {
          "code": "figo-iv",
          "display": "FIGO IV",
          "definition": "Distant metastasis beyond the peritoneal cavity"
        },
        {
          "code": "figo-iva",
          "display": "FIGO IVA",
          "definition": "Stage IV with spread to adjacent pelvic organs or pleural effusion with positive cytology (entity-specific definition)"
        },
        {
          "code": "figo-ivb",
          "display": "FIGO IVB",
          "definition": "Stage IV with distant metastasis including extra-abdominal organs and lymph nodes"
        },
        {
          "code": "figo-ivc",
          "display": "FIGO IVC",
          "definition": "Stage IV with distant metastasis (entity-specific definition)"
        }
      ]
    },
    {
      "code": "bismuth",
      "display": "Bismuth",
      "definition": "Classification system for hilar cholangiocarcinoma based on the extent of biliary involvement and resectability.",
      "concept": [
        {
          "code": "bismuth-i",
          "display": "Bismuth I",
          "definition": "Tumor below confluence of left and right hepatic ducts"
        },
        {
          "code": "bismuth-ii",
          "display": "Bismuth II",
          "definition": "Tumor reaching confluence but not involving secondary ducts"
        },
        {
          "code": "bismuth-iii",
          "display": "Bismuth III",
          "definition": "Tumor involving confluence and either right or left secondary ducts"
        },
        {
          "code": "bismuth-iiia",
          "display": "Bismuth IIIA",
          "definition": "Tumor involving confluence and right secondary ducts"
        },
        {
          "code": "bismuth-iiib",
          "display": "Bismuth IIIB",
          "definition": "Tumor involving confluence and left secondary ducts"
        },
        {
          "code": "bismuth-iv",
          "display": "Bismuth IV",
          "definition": "Tumor involving confluence and both right and left secondary ducts"
        }
      ]
    },
    {
      "code": "masaoka",
      "display": "Masaoka",
      "definition": "Staging system for thymomas based on invasiveness and extent of disease.",
      "concept": [
        {
          "code": "masaoka-i",
          "display": "Masaoka I",
          "definition": "Encapsulated tumor without invasion"
        },
        {
          "code": "masaoka-ii",
          "display": "Masaoka II",
          "definition": "Invasion into surrounding fatty tissue or mediastinal pleura"
        },
        {
          "code": "masaoka-iii",
          "display": "Masaoka III",
          "definition": "Invasion into neighboring organs"
        },
        {
          "code": "masaoka-iv",
          "display": "Masaoka IV",
          "definition": "Pleural or pericardial dissemination"
        },
        {
          "code": "masaoka-iva",
          "display": "Masaoka IVA",
          "definition": "Pleural or pericardial implants"
        },
        {
          "code": "masaoka-ivb",
          "display": "Masaoka IVB",
          "definition": "Lymphogenous or hematogenous metastasis"
        }
      ]
    },
    {
      "code": "mitoserate-gist",
      "display": "Mitoserate-GIST",
      "definition": "Mitotic rate assessment for gastrointestinal stromal tumors.",
      "concept": [
        {
          "code": "mitoserate-gist-n",
          "display": "Mitoserate-GIST Niedrig",
          "definition": "Low mitotic rate: ≤5 mitoses per 50 HPF"
        },
        {
          "code": "mitoserate-gist-h",
          "display": "Mitoserate-GIST Hoch",
          "definition": "High mitotic rate: >5 mitoses per 50 HPF"
        }
      ]
    },
    {
      "code": "p16",
      "display": "p16",
      "definition": "p16 protein expression status assessment.",
      "concept": [
        {
          "code": "p16-p",
          "display": "p16 Positiv",
          "definition": "Positive p16 protein expression"
        },
        {
          "code": "p16-n",
          "display": "p16 Negativ",
          "definition": "Negative p16 protein expression"
        }
      ]
    },
    {
      "code": "eutos-score",
      "display": "EUTOS-Score",
      "definition": "European Treatment and Outcome Study prognostic score for chronic myeloid leukemia.",
      "concept": [
        {
          "code": "eutos-score-n",
          "display": "EUTOS-Score Niedrigrisiko",
          "definition": "Low risk EUTOS score: ≤87"
        },
        {
          "code": "eutos-score-h",
          "display": "EUTOS-Score Hochrisiko",
          "definition": "High risk EUTOS score: >87"
        }
      ]
    },
    {
      "code": "sanz-score",
      "display": "Sanz-Score",
      "definition": "Risk assessment score for acute promyelocytic leukemia.",
      "concept": [
        {
          "code": "sanz-score-n",
          "display": "Sanz-Score Niedrig",
          "definition": "Low risk: WBC <10x10⁹/L and platelets >40x10⁹/L"
        },
        {
          "code": "sanz-score-i",
          "display": "Sanz-Score Intermediär",
          "definition": "Intermediate risk: WBC <10x10⁹/L and platelets ≤40x10⁹/L"
        },
        {
          "code": "sanz-score-h",
          "display": "Sanz-Score Hoch",
          "definition": "High risk: WBC ≥10x10⁹/L"
        }
      ]
    },
    {
      "code": "ipi",
      "display": "IPI",
      "definition": "International Prognostic Index for aggressive non-Hodgkin lymphoma.",
      "concept": [
        {
          "code": "ipi-n",
          "display": "IPI Niedrig",
          "definition": "Low risk: 0-1 risk factors"
        },
        {
          "code": "ipi-ni",
          "display": "IPI Niedrig-Intermediär",
          "definition": "Low-intermediate risk: 2 risk factors"
        },
        {
          "code": "ipi-hi",
          "display": "IPI Hoch-Intermediär",
          "definition": "High-intermediate risk: 3 risk factors"
        },
        {
          "code": "ipi-h",
          "display": "IPI Hoch",
          "definition": "High risk: 4-5 risk factors"
        }
      ]
    },
    {
      "code": "flipi",
      "display": "FLIPI",
      "definition": "Follicular Lymphoma International Prognostic Index.",
      "concept": [
        {
          "code": "flipi-l",
          "display": "FLIPI Low risk",
          "definition": "Low risk: 0-1 risk factors"
        },
        {
          "code": "flipi-i",
          "display": "FLIPI Intermediate risk",
          "definition": "Intermediate risk: 2 risk factors"
        },
        {
          "code": "flipi-h",
          "display": "FLIPI High risk",
          "definition": "High risk: ≥3 risk factors"
        }
      ]
    },
    {
      "code": "mipi",
      "display": "MIPI",
      "definition": "Mantle Cell Lymphoma International Prognostic Index.",
      "concept": [
        {
          "code": "mipi-n",
          "display": "MIPI Niedrig",
          "definition": "Low risk MIPI score"
        },
        {
          "code": "mipi-i",
          "display": "MIPI Intermediär",
          "definition": "Intermediate risk MIPI score"
        },
        {
          "code": "mipi-h",
          "display": "MIPI Hoch",
          "definition": "High risk MIPI score"
        }
      ]
    },
    {
      "code": "risikogruppen-ghsg",
      "display": "Risikogruppen GHSG",
      "definition": "German Hodgkin Study Group risk stratification.",
      "concept": [
        {
          "code": "risikogruppen-ghsg-fr",
          "display": "GHSG Frühe",
          "definition": "Early favorable risk group"
        },
        {
          "code": "risikogruppen-ghsg-i",
          "display": "GHSG Intermediär",
          "definition": "Intermediate risk group"
        },
        {
          "code": "risikogruppen-ghsg-fo",
          "display": "GHSG Fortgeschritten",
          "definition": "Advanced risk group"
        }
      ]
    },
    {
      "code": "ipss",
      "display": "IPSS",
      "definition": "International Prognostic Scoring System for myelodysplastic syndromes.",
      "concept": [
        {
          "code": "ipss-l",
          "display": "IPSS Low",
          "definition": "Low risk: score 0"
        },
        {
          "code": "ipss-i1",
          "display": "IPSS Intermediate-I",
          "definition": "Intermediate-1 risk: score 0.5-1.0"
        },
        {
          "code": "ipss-i2",
          "display": "IPSS Intermediate-II",
          "definition": "Intermediate-2 risk: score 1.5-2.0"
        },
        {
          "code": "ipss-h",
          "display": "IPSS High risk",
          "definition": "High risk: score ≥2.5"
        }
      ]
    },
    {
      "code": "her2-neu",
      "display": "HER2-neu",
      "definition": "HER2-neu protein expression and gene amplification status.",
      "concept": [
        {
          "code": "her2-neu-p",
          "display": "HER2-neu Positiv",
          "definition": "Positive HER2-neu status (IHC 3+ or FISH amplified)"
        },
        {
          "code": "her2-neu-n",
          "display": "HER2-neu Negativ",
          "definition": "Negative HER2-neu status (IHC 0-1+ or FISH not amplified)"
        }
      ]
    }
  ]
}